SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biogen
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1686 75 0 BIIB
Emcee:  Harold Engstrom Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1486Cacaito, HAVE YOU SEEN THIS??????>>>>>>>>>http://www.Bluegreen-12/27/2002
1485Interesting...... as of last year, Kantor *WAS* an H&Q analyst. Howeverscaram(o)uche-12/26/2002
1484H&Q likes Biogen -- still. wrhambrecht.comfred hayes-12/26/2002
1483Biogen Scientists Advance Understanding of Inflammatory Bowel Disease With New Dmopgcw-12/18/2002
1482Mult Scler 2002 Dec;8(6):492-4 Low interferon gamma producers are better treatHarold Engstrom-12/16/2002
1481BGEN: Avonex Price Increase of 4.9% Effective 2H (In-line, High Risk) asmopgcw-12/13/2002
1480Better have a look at the link provided by Nigel on the Elan board. It challengefred hayes-12/2/2002
1479From Barron's on Merrill's sell: <snip> One indisputable result mopgcw-12/1/2002
1478Biogen, Inc. (BGEN) BGEN: Preliminary Positive Results with 2H (Inmopgcw-11/26/2002
1477A little different view: wrhambrecht.com fredfred hayes-11/26/2002
1476USB Piper downgrades to underperform w/ $34 target.mopgcw-11/19/2002
1475From SSB on the expanded Avonex label: Biogen, Inc. (BGEN) BGEN: FDA Approves Fmopgcw-11/14/2002
1474From GS 10/21: BGEN reported Q3 of $0.37, excluding a pretax charge of $18MM, $mopgcw-11/12/2002
1473From GS 11/7: Teva failed in its Phase III trial of Copaxone to treat primary pmopgcw-11/12/2002
1472They get Class-2 designation for Amevive From SSB: Biogen, Inc. (BGEN) BGEN: Rmopgcw-9/12/2002
1471wrhambrecht.com bgen: Initiating Coverage With A Buy Rating — Compelling Valuatmopgcw-9/6/2002
1470The numbers cited indicate flat growth from last year through 2004. Also: (1) Harold Engstrom-9/5/2002
1469From GS 7/30: Long Term EPS Growth is expected to be 22% a year. BGEN reportedmopgcw-9/5/2002
1468But good thought, thanks! (eom)scaram(o)uche-8/29/2002
1467>> Would the PIIa oral results be in the air? << Got me. My researscaram(o)uche-8/29/2002
1466Near term - Q4 Adentri IV formulation P1 trial completion Would the PIIa oral remichael_f_murphy-8/29/2002
1465The intensity of the short attack on CVTX might imply that a research boutique hscaram(o)uche-8/29/2002
1464From Briefing.com: >>9:29AM Biogen: Avonex mkt more competitive than thoutuck-8/28/2002
1463After Biogen files the response to the CRL, THEN the Fda decides if it will be CCacaito-7/22/2002
1462Well, I did not know that it was channel stuffing. And in fact salesmen makingaknahow-7/19/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News